Brillet G, Deray G, Lucsko M, Faucher C, Aubert P, Rottembourg J, Jacobs C
Service de Néphrologie, Hôpital Pittié-Salpêtrière, Paris.
Nephrologie. 1993;14(5):227-9.
Renal failure secondary to CDDP is due to acute tubular necrosis and is usually reversible. We report 4 cases of definitive renal failure secondary to administration of cisplatin (CDDP). Three women and one man, mean age 40 +/- 8 years (24 to 64 years), at onset of dialysis are reported. They had received 1 to 4 courses of CDDP for an endometrial carcinoma (n = 2), a breast carcinoma or a thymoma. The mean total dose of CDDP was 447 +/- 169 mg (160 to 900 mg). There was no additional nephrotoxic drug. Before treatment serum creatinine concentration was normal (77 +/- 7 mumol per liter) in all patients. In 2 cases dehydration (due to vomiting and use of mannitol) occurred during CDDP treatment. One patient was treated 30 days after a nephrectomy. At the onset of dialysis, renal ultrasound was normal. In 3 cases dialysis was necessary within 15 days following chemotherapy. In one case renal function deteriorated progressively to end stage renal failure 12 months after CDDP treatment. Dialysis was performed in 3 cases by hemodialysis and in one patient by peritoneal dialysis. All patients remained more than 6 months on dialysis. Three patients died from their cancer. One patient, being considered cured from his thymoma, is currently being evaluated for a kidney transplantation. Our observations outline the potential severity of CDDP nephrotoxicity. Systemic hydration with serial serum creatinine measurements are mandatory during and after CDDP administration these patients.
顺铂导致的肾衰竭是由急性肾小管坏死引起的,通常是可逆的。我们报告了4例因使用顺铂(CDDP)导致的明确肾衰竭病例。报告了3名女性和1名男性,透析开始时平均年龄为40±8岁(24至64岁)。他们因子宫内膜癌(n = 2)、乳腺癌或胸腺瘤接受了1至4个疗程的CDDP治疗。CDDP的平均总剂量为447±169毫克(160至900毫克)。没有使用其他肾毒性药物。所有患者治疗前血清肌酐浓度均正常(77±7微摩尔/升)。2例在CDDP治疗期间出现脱水(由于呕吐和使用甘露醇)。1例患者在肾切除术后30天接受治疗。透析开始时,肾脏超声检查正常。3例在化疗后15天内需要透析。1例患者在CDDP治疗12个月后肾功能逐渐恶化为终末期肾衰竭。3例患者通过血液透析进行透析,1例患者通过腹膜透析进行透析。所有患者透析时间均超过6个月。3例患者死于癌症。1例被认为胸腺瘤已治愈的患者目前正在接受肾移植评估。我们的观察结果概述了CDDP肾毒性的潜在严重性。对于这些患者,在CDDP给药期间和之后必须进行全身水化并连续测量血清肌酐。